Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough
As of the close of play on February 12, consensus sentiment around Summit Therapeutics (NASDAQ:SMMT) was moderately bullish.
Summit Therapeutics Inc. (SMMT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Polymer Capital Management Angus Yuk Chi Wai | 1,421,155 | $24,856,001 | +74% | 3.54% |
| 2. | Squarepoint Ops LLC Maxime Fortin (Cio) | 715,410 | $12,512,521 | +552% | 0.01% |
| 3. | QVT Financial Daniel Gold | 360,524 | $6,305,565 | 0.54% | |
| 4. | 356,900 | $6,242,181 | +8% | 0.06% | |
| 5. | Sculptor Capital Daniel S. Och | 356,900 | $6,242,181 | +8% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.74 | 533,617 | $9,999,982.58 | 32,057,147 | 2025-10-21 | Filing | |
| $18.74 | 26,680 | $499,983.20 | 76,680 | 2025-10-21 | Filing | |
| $18.74 | 26,680 | $499,983.20 | 76,680 | 2025-10-21 | Filing | |
| $18.07 | 5,000 | $90,350.00 | 556,093,090 | 2025-09-11 | Filing | |
| $17.68 | 333,394 | $5,894,405.92 | 556,088,090 | 2025-09-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.44 | 13,713 | $60,885.72 | 0 | 2020-11-30 | Filing | |
| $4.39 | 29,569 | $129,807.91 | 0 | 2020-11-27 | Filing | |
| $4.32 | 12,070 | $52,142.40 | 0 | 2020-11-25 | Filing | |
| $4.21 | 11,374 | $47,884.54 | 0 | 2020-11-24 | Filing | |
| $4.40 | 6,987 | $30,742.80 | 0 | 2020-11-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,177,220 | $195,489,577 | 0% | |
| 2. | 9,361,921 | $163,739,998 | 0% | |
| 3. | 6,636,361 | $116,069,954 | 0% | |
| 4. | 3,147,480 | $55,063,414 | 0% | |
| 5. | 1,383,775 | $24,381,751 | 0.02% |
News See All
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In?
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the most oversold NASDAQ stocks to invest in. On February 2, H.C. Wainwright reaffirmed a Buy rating on Summit Therapeutics Inc.
13 Oversold NASDAQ Stocks to Invest In
On February 6, Richard Bernstein, Richard Bernstein Advisors CEO, appeared on CNBC’s 'The Exchange' to talk about the state of equity markets.
FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the stocks that should double by 2030.
15 Stocks That Should Double by 2030
On January 27, Sherry Paul, Morgan Stanley senior portfolio manager, joined CNBC's 'Closing Bell' to discuss the state of equity markets and whether more volatility is ahead.
Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive
On January 14, H.C. Wainwright analyst Mitchell Kapoor reaffirmed his optimistic outlook on Summit Therapeutics (NASDAQ:SMMT).
15 Large Cap Stocks Under $100 With Huge Upside Potential
The large-cap stock universe comprises mature companies with market capitalizations ranging between $10 billion and $200 billion.
Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best stocks under $25 to buy now. Cantor Fitzgerald reaffirmed its Overweight rating on Summit Therapeutics Inc.
15 Best Stocks Under $25 to Buy Now
Stock futures were marginally lower early December 29, as traders grabbed profits at record index levels and exited prominent technology names and precious metals following an explosive rally.
Hedge Fund Resource Center Billionaire Hedge Funds
